Welcome to this eCME on Pulmonary Arterial Hypertension (PAH) and the interplay between clinical pharmacology and clinical outcome.
Prof. Marion Delcroix head of pneumology at UZ Leuven presents with Prof. Lorenz Van der Linden PharmD how and why switching treatments within the NO pathway can improve the patient outcomes.
Discover with this eCME how differences between riociguat and PDE5i result in different clinical outcomes.
MD - University Hospital Leuven
Marion Delcroix, MD, PhD, graduated from the Free University of Brussels, where she specialized in respiratory medicine. She is currently Professor of Medicine and of Respiratory Physiology at the Universities of Leuven and Kortrijk, Belgium. She is Head of the Pulmonary Hypertension Program, in charge of the Respiratory High Care Unit and Vice-Chair of the Council for Rare Diseases of the University Hospitals of Leuven. She has been involved in the routine care of over 2000 patients with PH and has participated in main pivotal trials for the treatment of PAH. Marion Delcroix was a task force member at the 3rd to 6th World Symposia on PH, a nucleus member of the Working Group on Pulmonary Circulation & RV Function of the European Society of Cardiology (ESC) and is a founding member of the International CTEPH Association (ICA). She has over 200 publications, with research interests focusing on pulmonary circulation and gas exchange, cardiac imaging and the role of inflammation in the pathogenesis of PAH and CTEPH and is an editorial board member of the European Respiratory Journal. Lastly, she was involved as core member for PH in the European Reference Network (ERN)-lung and as Assembly Head for Pulmonary Vascular Diseases of the European Respiratory Society (ERS). She is a fellow of the ESC and of the ERS.
PharmD - University Hospital Leuven
Mr Lorenz Van der Linden is currently working as a Hospital Pharmacist in a large teaching hospital (UZ Leuven, Belgium). His work focuses on investigating, developing and implementing clinical pharmacy services in selected patient populations (e.g. geriatric inpatients). Mr Lorenz Van der Linden graduated as a hospital pharmacist in 2008, after which he followed a 2-year post-graduate course in clinical pharmacy. In 2018, he obtained his PhD (KULeuven, Belgium) for his work on improving drug use in older inpatients. He is invested in improving drug use and clinical outcome in complex, multimorbid and frequently polymedicated older persons.
Een holistische benadering van de antistolling van oudere patiënten met niet-valvulair voorkamer fibrillatie: de lessen die we kunnen trekken uit gerandomiseerde klinische studies en gegevens uit de dagelijkse praktijk.